Peregrine Pharmaceuticals Trading Higher Following Brain Cancer Treatment Results
Shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) traded 15% higher earlier Monday following an announcement from company officials that the firm's brain cancer treatment showed positive results, reports MarketWatch. Shares of the company continue to trade 19.28% higher Monday afternoon at $1.98. Peregrine Pharmaceuticals is a biopharmaceutical company.
The company is focused on the research, development and commercialization of novel therapeutics for cancer and a wide range of viral diseases. The company has reported $22.2 million in sales over the past 12 months and is expected to report $28.6 million in sales in the next fiscal year.
